Drug Profile
Filgrastim biosimilar - Pfizer
Alternative Names: FILGRASTIM-AAFI; Nivestim; NivestymLatest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Hospira
- Developer Pfizer
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Febrile neutropenia; Neutropenia